Axios · Natalie Breymeyer ·

Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, raised a $25M Series A

Altis Labs, an AI software company for drug development, raised a $25 million Series A, CEO Felix Baldauf-Lenschen tells Axios Pro.

AI Venture Capital

In this story Altis Labs

Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, raised a $25M Series A

Lead Source

Axios — Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, raised a $25M Series A ↗

How this story grew

Coverage · 0 Discussion · 0

Sep 21Sep 22

Related stories

Dealroom.co: Faro, which develops data models and AI tools to speed up clinical trials, raised a $37.3M Series B co-led by Merck Global Health Innovation Fund and S32

Wall Street Journal: Network Bio, which is developing an AI foundation model from datasets of patient tissue and blood samples created by pooling access to biobanks, raised $50M

GeekWire: Resect AI, which is developing open-source tech to catch AI hallucinations before they happen, emerges from stealth with $25M from private equity investors

Axios: Epsilon Health, which contracts with radiologists who use its AI to generate image reports faster, emerges from stealth with a $20M Series A led by AlleyCorp

GamesBeat: Astromech, which uses genomic data to build predictive AI models of biological change, raised $20M at a $3.8B valuation, bringing its total funding to $60M

Discuss with AI

ChatGPT ↗ Claude ↗

← Back to TechSnif